medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2010, Number 08

<< Back Next >>

Ginecol Obstet Mex 2010; 78 (08)

Study and treatment of women in the climacteric and postmenopause. Point of view of the Mexican Association for the Study of Climacteric 2010

Language: Spanish
References: 368
Page: 423-440
PDF size: 425.49 Kb.


ABSTRACT

The life expectancy of Mexican women has increased to 80 years and thus the possibility of disease. This requires health professionals to remain current in the skills needed to provide optimal service. He has spent more than a century since released the first report of effective treatment to reduce or eliminate the symptoms of restorative therapy hypoestrogenism since then, much progress has been made in the study of the physiology and pathophysiology, there have been many observational studies and randomized controlled have shown that treatment have prolonged the life expectancy of women. The prescription of hormone replacement therapy should be based on knowledge of the clinical history of each patient, the mechanism of action of each drug, the risk-benefit of this and the real need to indicate them. The purpose of publicizing this “point view”, derived from the opinions of a group of scholars in this area of medical knowledge, is put at the disposal of the Mexican medical community an update on all aspects of care of women in the climacteric stage.


REFERENCES

  1. INTRODUCCIÓN.

  3. Fosbery WHS. Severe climacteric flushing successfully treated by ovarian extract. Br Med J 1897;i:1039

  4. Soules MR, Sherman S, Perot E, Rebar R, et al. Executive Summary: Stages of Reproductive Aging Workshop (STRAW). Climacteric 2001;4:267-272.

  5. Randolph JF, Crawford S, Dennerstein L, Cain K, Harlow SD. The value of follicle stimulating hormone concentration and clinical findings as markers of the late menopausal transition. J Clin Endocrinol Metab 2006;91:3034-3040.

  6. Estrogen and Progestagen use in posmenopausal women: July 2008 position statement of the North American Menopause Society. Menopause 2008;15(4):584-602.

  7. Utian Wulf H y col. Revisión de la Menopausia y el Envejecimiento en: Menopausia. Guía práctica para el médico. Traducción de la 3ª ed. México: Edición y Farmacia, 2007;p:10-12.

  8. Septién González JM, Morfín J, y col. Climaterio femenino. En: Programa de actualización continua en Ginecología y Obstetricia-3. Libro 1. México: Intersistemas, 2008;p:1-165.

  9. .

  11. SÍNTOMAS.

  13. Burger HG, Hale GE, Dennerstein L, Robertton DM. Cycle and hormonal changes during perimenopause: The key role of ovarian function. Menopause 2008:15(4):603-612.

  14. McLennan A, Moore LS. Oral oestrogen replacement therapy versus placebo for hot flushes. (Cochrane Review) Cochrane Database Syst Rev 2001;1 CD002978.

  15. Utian WH, et al. Health, Osteoporosis, Progestin, Estrogen. Fertil Steril 2001;75:1065-1079.

  16. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321-333.

  17. Arriaga M, Arteaga E, Bianchi M y col. Recomendaciones de tratamiento en la menopausia. Rev Chil Obstet Ginecol 2005;70(5):340-345.

  18. Birkhauser MH, Panay N, Archer DF, Barlow D. Updated practical recomendations for hormone replacement therapy in the peri-and menopause. Climacteric 2008;11:108-123.

  19. Lobo RA, Archer DF, Ettinger B, et al. NAMS Position Statement. Estrogen and Progestogen use in postmenopausal women. The North American Menopause Society. Menopause 2008;15(4):584-602.

  20. Sarduy N, Lugones B. II Consenso Cubano sobre Climaterio y Menopausia. Taller Nacional de Revisión y Actualización. Ciudad Habana, 14 y 15 de diciembre de 2006. Editorial CIMEQ. Sociedad Cubana de Ginecología y Obstetricia, Habana, Cuba, 2007.

  21. Carranza-Lira S. Actualidades en terapia hormonal durante el climaterio. México: Ediciones y Distribuciones Universum, 2008.

  22. Archer DF, Gambacciani M, Goldstein M, Pinkerton J, et al. Updated practical recommendations for hormone replacement therapy in the peri and postmenopause. Climacteric 2008;11:108-123.

  23. Panay NUK, Archer DF, Barlow D, Burger H, et al. The IMS Updated Recommendations on postmenopausal hormone therapy. Climacteric 2007;10:181-194.

  24. Guthrie JR, Politi M, Dennerstein L. Duration of vasomotor symptoms in middle-aged women: a longitudinal study. Menopause 2009, Feb 2. [Epub ahead of print].

  25. Freeman EW, Sammel MD, Lin H. Temporal association of hot flashes and depression in the transition to menopause. Menopause. 2009, Feb 2. [Epub ahead of print].

  26. Utian W. NAMS confirms its support of FDA warning about custom-compounded bioidentical hormone therapy. Cleveland, Ohio. Menopause, February 5, 2009.

  27. Grambell RD, Natrajan PK. Moderate dosage estrogen-androgen therapy improves continuation rates in postmenopausal women: impact of the WHI reports. Climacteric 2006;9:224-233.

  28. Canto de Zetina TE. El tratamiento hormonal para el control de los síntomas. Revista de Endocrinología y Nutrición 2006;14(3):171-176.

  29. Utian WH. Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review. Health Qual Life Outcomes 2005;3:47-56.

  30. Bruce D, Rymer J. Symptoms of the menopause. Best Practice and Research Clinical Obstetrics and Gynaecology 2009;23:25-32.

  31. Archer DF, Dupont CM, Constantine GD, Pickar JH, Olivier S, et al. Desvenlafaxine for treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety. AJOG 2009;200:238.e1-238.e10.

  32. Million Women Study Collaborators. Breast Cancer, hormone replacement therapy in the Million Women Study. Lancet 2003;362:419-422.

  33. Nelson HD, Vesco KK, Haney E, Fu R, et al. Nonhormonal Therapies for Menopausal Hot Flashes. Systematic Review and Meta-analysis. JAMA 2006;95(17):2057.

  34. < h t t p : / / w w w. e m e a . e u r o p a . e u / p d f s / g e n e r a l / d i r e c t / pr/29987307>. En pdf.

  35. Buijs C, Mom CH, Willemse PH, Marike Boezen H, et al. Venlafaxine versus clonidine for the treatment of hot flashes in breast cancer patients: a double-blind, randomized cross-over study. Breast Cancer Res Treat 2008 Aug 1.

  36. Lolprinzi CL, Barton DL, Sloan JA, Novontny PJ, Wolf S. Newer antidepressants for hot flashes — should their efficacy still be up for debate? Menopause 2009;16(1):184.

  37. Cheema D, Coomarasamy A, El-Toukhy T. Non-hormonal therapy of post-menopausal vasomotor symptoms: a structured evidencebased review. Arch Gynecol Obstet 2007;276(5):463-469.

  38. Wong VC, Lim CE, Luo X, Wong WS. Current alternative and complementary therapies used in menopause. Gynecol Endocrinol 2009;25(3):166-174.

  39. Rees M. Alternative treatments for the menopause. Best Pract Res Clin Obstet Gynaecol 2009;23(1):151-161.

  40. Montoya JJ. Principales problemas urogenitales y sus manifestaciones. En: Septién JM, editor. Climaterio: estudio, diagnóstico y tratamiento. México: Intersistemas, 2000;p:158-170.

  41. Morfin J. Importancia de los receptores hormonales sobre los órganos pélvicos y el piso perineal. En: Septién JM (ed). Climaterio: estudio, diagnóstico y tratamiento. México: Intersistemas, 2000;p:155-157.

  42. Samsoie G. Urogenital aging: a hidden problem. Am J Obstet Gynecol 1998;178:245-249.

  43. Samsoie G. Lower urinary tract symptoms at menopause. Update on Menopause management. IMS 2007;p:11-12.

  44. Montoya JJ. Cirugía del prolapso genital en la mujer climatérica. En: 40 años de vida profesional del Dr. Carlos Fernández del Castillo. Libro Homenaje. México: MPM, 1996;p:143-147.

  45. Brubaker L. Urinary urgency and frecuency: what should a clinican do? Obstet Ginecol 2005;105:666-667.

  46. Danforth KN. Risk factors for urinary incontinence among middle-aged women. Am J Obstet 2006;194:339-345.

  47. NAMS. Traducción de la 3ª edición de: Menopausia: guía práctica para el médico. México: Edición y Farmacia, 2007.

  48. Birkhäuser, M. Health Plan for the adult woman. Management handbook. London: Taylor & Francis, 2005.

  50. PSICOSEXUALIDAD.

  52. Birkhäuser MH, et al. Updated practical recommendations for hormone replacement therapy in the peri- and postmenopause. Climacteric 2008;11:108-123.

  53. Vesco KK, Haney EM, Humphrey L, Fu R, Nelson HD. Influence of menopause on mood: a systematic review of cohort studies. Climacteric 2007;10:448-465.

  54. Morse CA, Dudley E, Guthrie J. Relationships between premenstrual complaints and perimenopausal experience. J Psychosomatic Obstetric Gynaecology (Australia) 1998;4:182-191.

  55. Avis NeE, Stellato CR, Longcope C. Longitudinal study of hormone levels and depression among women transitioning through menopause. Climacteric 2008;4(3):243-249.

  56. Schmidt PJ, Haq N, Rubinow DR. A longitudinal evaluation of the relationship between reproductive status and mood in perimenopausal women. Am J Psychiatry 2004;161:2238-2244.

  57. Caspi A, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2004;301:385-389.

  58. Korzun A, et al. Familiality of symptom dimensions in depression. Arch Gen Psychiatry 2004;61(5):468-474.

  59. Heim C, Plotsky PM, Nemeroff CB. Importance of studying the contributions of early adverse experience to neurobiological findings in depression. Neuropsychopharmacology 2004;29(4):641-648.

  60. Braga MF, et al. Stress impairs _ 1_ adrenoceptor-mediated noradrenergic facilitation of GABAergic transmission in the basolateral amigdala. Neuropsychopharmacology 2004;29(4):45-58.

  61. Hvas L. Menopausal women’s positive experience of growing older. Maturitas. 2006;54(3):245-251.

  62. Legorreta D, Tserotas K. Attitudes to ageing of perimenopausal women in Mexico and Panama. A comparative study. Climacteric 2008;11(2):187.

  63. Chedraui P, Perez-Lopez FR, Morales B, Hidalgo L. Depressive symptoms in climacteric women are related to menopausal symptom intensity and partner factors. Climacteric 2009 (Apr 22):1-9.

  64. Andrikoula M, Prelevic G. Menopausal hot flushes revisited. Climacteric 2009;12(1):3 -15.

  65. Moline M, Broch L, Zak R. Sleep problems across the life cycle in women. Curr Treat Options Neurol 2004;6(4):319-330.

  66. Becker D, Orr A, Weizman A, Kotler M, Pines A. Depressed mood through women’s reproductive cycle: correlation to mood at menopause. Climacteric. 2007;10(1):46-50.

  67. Parry BL. Perimenopausal depression. Am J Psychiatry 2008:23-27.

  68. APM: Diagnostic and Statistical Manual of Mental Disorders. DSMIV- TR. Washington: American Psychiatric Association, 2000.

  69. Palacios S. Advances in hormone replacement therapy: making the menopause manageable. BMC Women’s Health 2008;p:8- 22.

  70. Maclennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2004;(1):CD002978.

  71. Chedraui P, et al. Impaired quality of life among middle aged women: A multi-centre Latin American study. Maturitas 2008;(61):323-329.

  72. Sherwin BB. The impact of different doses of estrogen and progestin on mood and sexual behavior in postmenopausal women. J Endocrinol Metab 1991;72:336-343.

  73. Bouchard P, Archer DF, Panay N, Olivier S, Bessac L. Desvenlafaxine succinate is an effective treatment for menopausal vasomotor symptoms: a review of 3 clinical trials. Amsterdam menopause Symposium June 2007.

  74. Nelson HD, Vesco KK, Haney E, et al. Non hormonal therapies for menopausal hot flashes: systematic review and metaanalysis. JAMA 2006;295:2057-2071.

  75. Marín R, Guerra B, Alonso R, Ramírez CM, Díaz M. Estrogen activates classical and alternative mechanisms to orchestrate neuroprotection. Curr Neurovasc Res 2005;2(4): 287-301.

  76. Galea LA, Uban KA, Epp JR, Brummelte S, et al. Endocrine regulation of cognition and neuroplasticity: our pursuit to unveil the complex interaction between hormones, the brain, and behaviour. Can J Exp Psychol 2008;62(4):247-260.

  77. Howard M, Kravitz DO, Peter M, Meyer TE, et al. Cognitive functioning and sex steroid hormone gene polymorphisms in women at midlife. Am J Medicine 2006;19(9A:S94-S102.

  78. Behl C, Skutella T, Lezohuaalch F, et al. Neuroprotection against oxidative stress by estrogens structure activity relationship. Mol Pharmacol 1997;51:535-541.

  79. Donald GS, Wright DW, Kellermann AL. Does progesterone have neuroprotective properties? Ann Emerg Med 2008;51:164-172.

  80. Maki PM, Gast MJ, Vieweg AJ, Burriss SW, Yaffe K. Hormone therapy in menopausal women with cognitive complaints: a randomized, double-blind trial. Neurology 2007;69:1322-1330.

  81. Jacobs DM, et al. Cognitive function in nondemented older women who took estrogen after menopause. Neurology 1998;50:368-373.

  82. Maki PM, Resnick SM. Longitudinal effects of estrogen replacement therapy on PET cerebral blood flow and cognition. Neurobiol Aging 2000;21:373-383.

  83. Maki PM, et al. Enhanced verbal memory in nondemented elderly women receiving hormone-replacement therapy. Am J Psychiatry 2001;158:227-233.

  84. Resnick SM, et al. Effects of estrogen replacement therapy on PET cerebral blood flow and neuropsychological performance. Horm Behav 1998;34:171-182.

  85. Shaywitz SE, et al. Effect of estrogen on brain activation patterns in postmenopausal women during working memory tasks. JAMA 1999;281:1197-202.

  86. Henderson VW, et al. Reproductive stage and memory in the melbourne women’s midlife health project. Neurology 2003;60:1369-1371.

  87. Shumaker SA, Legault C, Rapp SR, et al for the WHIMS Investigators. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women’s Health Initiative Memory Study: a randomized controlled trial. JAMA 2003;289:2651-2662.

  88. Resnick SM, Espeland MA, Jaramillo SA, Hirsch C, et al. For the Women’s Health Initiative Memory Study. Postmenopausal hormone therapy and regional brain volumes. The WHIMS-MRI Study. Neurology 2009;72:135-142.

  89. Shumaker SA, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women’s Health Initiative Memory Study. JAMA 2004;291:2947-2958.

  90. Antonijevic IA, et al. Improvements in Sleep EEG patterns after open-label treatment with estradiol. Am J Obstet Gynecol 2000;182:277-282.

  91. Gambacciani M. Estrogen alone improves women’s subjective reports of sleep quality. Maturitas 2005;50:91-97.

  92. Xu H, et al. Estrogen reduces production of AD-related β-amyloid protein. Nat Med 1998;4:447-451.

  93. Henderson VW, et al. Estrogen did not improve cognition or global function in women with Alzheimer disease. Neurology 2000;54:295-301.

  94. Mulnard RA, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer’s Disease Cooperative Study. JAMA 2000;283:1007-1015.

  95. Zandi PP, et al. Hormonal therapy use is associated with reduced risk or delayed onset of Alzheimer’s disease. JAMA 2002;288:2123-2129.

  96. Daley A, MacArthur C, Mutrie N, Stokes-Lampard H. Phytoestrogens for vasomotor symptoms and exercise for vasomotor symptoms. Cochrane Database Syst Rev 2007;(4):CD001395 and CD006108.

  97. Pfaus JG, Scepkowski LA. The Biologic basis for libido. Current Sexual Health Reports 2005;2:95-100.

  98. McCoy N, Davidson M. A longitudinal study of the effects of menopause on sexuality. Maturitas 1985;7:203-210.

  99. Myers L. Methodological review and meta-analysis of sexuality and menopause research. Neurosciences Biobehav Rev 1995;19(2):331-341.

  100. Bachmann GA, Leiblum SR. Sexuality in sexagenarian women. JAMA 1983;249(2): 195-198.

  101. Dennerstein L, Smith AM, Morse CA, et al. Sexuality and the menopause. J Psychosom Obstetric Gynecology 1994;15:59-66.

  102. Graziottin A, Leiblum SR. Biological and psychosocial pathophysiology of female sexual dysfunction during the menopausal transition. J Sex Med 2005;2(Suppl. 3):133-145.

  103. Bachmann G. Sexual function in the perimenopause. Perimenopausal Health Care 1993;20.

  104. Basson R. Female Sexual Response. The role of drugs in the management of its dysfunction. Obstet Gynecol 2006;98(2):350-353.

  105. Dennerstein L, Koochaki P, Barton I, Graziottin A. Hypoactive sexual desire disorder in menopausal women: a survey of Western European women. J Sex Med 2006;3:212-222;379-389.

  106. García Segura LM, Cardona-Gomez P, Naftolin F, et al. Estradiol up regulates Bcl-2 expression in adult brain neurons. Neuroreport 1998;9(4):593-597.

  107. Pearce J. Psychological and sexual symptoms associated with the menopause and effects of HRT. BJ Psychiatry 1995;167:163-173.

  108. Goldstein I, Meston C, Davis S, Traish AM, eds. Women’s Sexual Function and Dysfunction. Study, Diagnosis and Treatment. London: Taylor & Francis, 2005.

  109. Beard MK, Curtis LR. Libido, menopause, and estrogen replacement therapy. Postgraduate Medicine 1989;86(1):225-228.

  110. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, et al, and Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 2002;288(3):321-333.

  111. Dennerstein L, Dudley E. Sexuality, hormones and the menopausal transition. Maturitas 1997;26:83-93.

  112. Shifren JL, Braunstein GD, Simon JA, et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 2000;343:682-688.

  113. Simon J, Braunstein G, Nachtigall L, et al. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab 2005;90:5226-5233.

  114. Castelo-Branco C, Vicente JJ, Figueras F, San Juan A. Comparative effects of estrogens, plus androgens and tibolone on bone, lipid pattern and sexuality and postmenopausal women. J Menopause European Maturitas 2000;34:161-168.

  115. Liu JH. Therapeutic effects of progestins, androgens, and tibolone for menopausal symptoms. Am J Med 2005;19(118):88-92.

  116. World Health Organization (WHO). Defining Sexual Health: Report of a Technical Consultation on Sexual Health. WHO: Geneva, 2006.

  117. Blume EJ. Sexual dysfunction in middle-aged women: a multicenter Latin American study using the Female Sexual Function Index. Menopause 2009;16:6-10.

  119. MASA CORPORAL, ALIMENTACIÓN Y EJERCICIO.

  121. .

  122. .

  123. Pisabarro R. Metabolismo y climaterio: la visión de un endocrinólogo. Rev Med Uruguay 2000;16:144-151.

  124. Lamberts SW, van den Beld AW, Van der Lely AJ. The endocrinology of aging. Science 1997;278(5337):419-424.

  125. Björntorp P. Obesity. A civilization syndrome. Obes Res 1993;1:206-222.

  126. Poehlman ET, Toth MJ, Fishman PS, Vaitkevicius P, et al. Sarcopenia in aging humans: the impact of menopause and disease. J Gerontol Biol Sci Med Sci 1995;50:73-77.

  127. De Pergola G, Zamboni M, Sciaraffia M, Turcato E, et al. Body fat accumulation is possibly responsible for lower dehydroepiandrosterone circulating levels in premenopausal obese women. Inter J Obes Rel Met Dis 1996;20(12):1105-1110.

  128. Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL. Increasing prevalence of overweight among US adults: The National Health and Nutrition Examination Surveys, 1960 to 1991. JAMA 1994;272:205-11. (Comments)

  129. Pasquali R, Casimirri F, Labate AM, Tortelli O, et al. Body weight, fat distribution and the menopausal status in women. Int J Obes 1994;18:614-621.

  130. Poehlman ET, Toth MJ, Gardner AW. Changes in energy balance and body composition at menopause: A controlled longitudinal study. Ann Intern Med 1995;123:673-675.

  131. Friedman JE, Dohm GL, Leggett-Frazier N, Elton CW, et al. Restoration of insulin responsiveness in skeletal muscle of morbidly obese patients after weight loss: Effect on muscle glucose transport and glucose transporter GLUT 4. J Clin Invest 1992;89:701-705.

  132. Hardin D, Azzareli B, Edwards J, Wigglesworth J, et al. Mechanisms of enhanced insulin sensitivity in endurancetrained athletes: effects on blood flow and differential expres sion of GLUT 4 in skeletal muscles. J Clin Endocrinol Metab 1995;80(8):2437-2446.

  133. Maron DJ, Fair JM, Haskell WL. Saturated fat intake and insulin resistance in men with coronary artery disease. Circulation 1991;84:2020-2027.

  134. Storlien LH, Kriketos AD, Calvert GD, Baur LA, Jenkins AB. Fatty acids, triglycerides and syndromes of insulin resistance. Prostaglandins Leukot Essent Fatty Acids 1997;57(4-5): 379-385.

  135. The 7th IMS WORKSHOP, Update on Menopause Management. A global consensus meeting for the development of a revised IMS Position Statement. Budapest February 17-19, 2007.

  136. Sanchez-Castillo CP, Velazquez-Monroy O, Lara-Esqueda A, Berber A, et al. Diabetes and hypertension increases in a society with abdominal obesity: results of the Mexican National Health Survey 2000. Pub Health Nutr 2004;8:53-60.

  137. González-Barranco J. Obesidad: problema de salud pública en México. Nutrición Clínica 2002;5:213-218.

  138. OECD health data 2007, statistics and indicators for 30 countries. http://www.oecd.org/document/30/0,2340,en_2649_374 07_12968734_1_1_1_37407,00.html.

  139. O’ Sullivan AJ, Ho KKY. A comparison of the effects of oral and transdermal estrogen replacement on insulin sensitivity in postmenopausal women. J Clin Endocrinol Metab 1995;80:1783-1788.

  140. Oestrogen and progestogen hormone replacement therapy for peri-menopausal and post-menopausal women: weight and body fat distribution (Review) Cochrane Database of Systematic Reviews, Issue 1, 2009. The Cochrane Collaboration. Published by JohnWiley & Sons, DOI: 10.1002/14651858.CD001018.

  141. Arellano-Montaño S, Bastarrachea-Sosa RA, Bourges-Rodríguez H, Calzada-León R, y col. La obesidad en México. Rev End Nut 2004;12:S80-S87.

  142. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006;444:881-887.

  143. Reeder BA, Senthiselvan A, Despres JP. The association of cardiovascular disease risk factors with abdominal obesity in Canada. Can Med Assoc J 1997;157:S39-45.

  144. Chen MM, Lear SA, Frohlich JJ, Birmingham CL. Intraobserver and interobserver realiability of waist circumference and the waist-to-hip ratio. Obes Res 2001;9:651.

  145. Pouliot MC, Despres JP, Lemieux S, Moorjani S, et al. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol 1994;73:460-468.

  146. Secretaría de Salud (México). Norma Oficial Mexicana NOM-043- SSA2-2005, Servicios básicos de salud. Promoción y educación para la salud en materia alimentaria. Criterios para brindar orientación. Diario Oficial de la Federación, 23 de enero del 2006.

  147. Toth MJ, Tchernof A, Sites CK, Poehlman ET. Effect of menopausal status on body composition and abdominal fat distribution. Int J Obes Relat Metab Disord 2000;24:226-231.

  148. Wu SI, Chou P, Tsai ST. The impact of years since menopause on the development of impaired glucose tolerance. J Clin Epidemiol 2001;54:117-120.

  149. Ley CJ, Lees B, Stevenson JC. Sex- and menopause-associated changes in body fat distribution. Am J Clin Nutr 1992;5:950-954.

  150. Svendsen OL, Hassager C, Christiansen C. Age and menopause- associated variations in body composition and fat distribution in healthy women as measured by dual-energy X-ray absorptiometry. Metabolism 1995;44:369-373.

  151. Cagnacci A, Soldani R, Carriero PL, Paoletti AM, et al. Effects of low doses of transdermal 17[beta]-estradiol on carbohydrate metabolism in postmenopausal women. J Clin Endocrinol Metab 1992;74:1396-1400.

  152. Kimmerle R, Heinemann L, Heise T, Bender R, et al. Influence of continuous combined estradiol-norethisterone acetate preparations on insulin sensitivity in postmenopausal nondiabetic women. Menopause 1999;6:36-42.

  153. Duncan AC, Lyall H, Roberts RN, Petrie JR, et al. The effect of estradiol and a combined estradiol/progestagen preparation on insulin sensitivity in healthy postmenopausal women. J Clin Endocrinol Metab 1999;84:2402-2407.

  154. Cucinelli F, Paparella P, Soranna L, Barini A, et al. Differential effect of transdermal estrogen plus progestagen replacement therapy on insulin metabolism in postmenopausal women: relation to their insulinemic secretion. Eur J Endocrinol 1999;140:215-223.

  155. Mattiasson I, Rendell M, Tornquist C, Jeppsson S, Hulthen UL. Effects of estrogen replacement therapy on abdominal fat compartments as related to glucose and lipid metabolism in early postmenopausal women. Horm Metab Res 2002;34:583-588.

  156. Walker RJ, Lewis-Barned NJ, Sutherland WH, Goulding A, et al. The effects of sequential combined oral 17[beta]-estradiol and norethisterone acetate on insulin sensitivity and body composition in healthy postmenopausal women: a randomized single blind placebo-controlled study. Menopause 2001;8:27-32.

  157. NAMS. Menopausia: guía práctica para el médico. Riesgo de enfermedad. Traducción de la 3a edición. México: Edición y Farmacia, 2007:p:125-143.

  158. NAMS Position Statement. Menopause 2008;15:584-602.

  160. MASA ÓSEA.

  162. National Osteoporosis Fundation. Clinician’s Guide to prevention and treatment of osteoporosis 2008. Disponible en http:// www.nof.org/professionals//Clinicians_Guide.htm. Consultado el 18 de marzo, 2009.

  163. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis and Therapy. Osteoporosis prevention, diagnosis and therapy. JAMA 2001;85:785-795.

  164. Allbright F. Postmenopausal osteoporosis. Trans Assoc Am Physicians 1940;55:298-305.

  165. Consensus Development Conference. Diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 1993;94:646-650.

  166. Woolf AD, Akesson K. Osteoporosis. Atlas de investigación y tratamiento. Oxford: Atlas Medical Publishing, 2008;p:1-22.

  167. Chesnut CH. Osteoporosis, an undiagnosed disease. JAMA 2001;286:2865-2866.

  168. Kanis JA, Johnell O. Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int 2005;16:229-238.

  169. Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 2007;22:465-475.

  170. Delmas PD. Hormone replacement therapy in the prevention and treatment of osteoporosis. Osteoporosis Int 1997;7(Suppl.):s3-s7.

  171. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis of osteoporosis. Endocr Rev 2001;21:115-137.

  172. Srivastava S, Weitzmann MN, Kimble RB, et al. Estrogen blocks M-CSF gene expression and osteoclast formation by regulating phosphorylation of Egr-1 and its interaction with Sp-1. J Clin Invest 1998;102:1850-1859.

  173. Srivastava S, Weitzmann MN, Cenci S, et al. Estrogen decreases TNF expression by blocking JNK activity and the resulting production of c-Jun and Jun D. J Clin Invest 1999;104:503-513.

  174. Sunyer T, Lewis J, Collin-Osdoby P, et al. Estrogen’s bone-protective effects may involve differential IL-1 receptor regulation in human osteoclast-like cells. J Cllin Invest 1999;103:1409-1418.

  175. Simonnet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-319.

  176. Srivastava S, Toraldo G, Weitzmann MN, et al. Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-kB ligand (RANKL)-induced JNK activation. J Biol Chem 2001;276:8836-8840.

  177. Manolagas SC, Kousteni S, Jilka Rl. Sex steroids and bone. Rec Prog Horm Res 2002;57:385-409.

  178. Hernández Bueno JA, Bujalil Montenegro K. Terapia de reemplazo hormonal, terapia estrogénica. En: García Hernández PA, Barreira Mercado E, Cons Molina F y col (eds). Avances en osteoporosis. México: AMMOM-Grupo Editorial M&M, 2008;p:265-282.

  179. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-1037.

  180. Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of non-vertebral fractures: a meta-analysis of randomized trials. JAMA 2001;285:2891-2897.

  181. Cauley JA, Robbins J, Chen Z, et al for the Women’s Health Initiative Investigators. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. JAMA 2003;290:1729-1738.

  182. Anderson GL, Limacher M, Assaf AR, for the Women’s Health Initiative Steering Comitee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized trial. JAMA 2004;291:1701-1712.

  183. Cummings SR, Ettinger B, Delmas PD, et al for the LIFT Study Investigators.The Effects of Tibolone in Older Postmenopausal Women. N Engl J Med 2008;359:697-708.

  184. NAMS Position Statement. Menopause 2008;15:584-602.

  185. Birkhauser M, et al. Updated practical recommendations for hormonal replacement therapy in the peri and postmenopause. Climacteric 2008;11:108-123.

  186. Kanis J, Burlet N, Cooper C, et al. On behalf of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008;19:399-428.

  187. Black DM, et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertabral fractures. Lancet 1996;348:1535-41.

  188. Cummings SR, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. JAMA 1998;280:2077-82.

  189. Harris ST, et al. Effects of risendronate treatment on vertebral and nonvertebral fractures in wome n with postemenopausal osteoporosis. JAMA 1999;282:1344-1352.

  190. Reginster JY, et al. Randomized trial of the effects of risendronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporosis Int 2000;11:83-91.

  191. Mc Clung MR, Geusens P, Miller P, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001;344:333-340.

  192. Chesnut IC, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241-1249.

  193. Delmas PD, et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significan reduction in vertebral fracture risk: results from the BONE study. Osteoporosis Int 2004;15:792-798.

  194. Delmas PD, et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from Dosing Intravenous Administration Study. Arthritis Rheum 2006;54:1838-1846.

  195. Black DM y col once yearly Zoledronic acid for treatment of postmenopausal osteoporosis. NEJM 2007;356:1809-1822.

  196. Lyles KW, et al. Zolendronic acid and clinical fractures and mortality alter hip fracture. NEJO 2007;357:1799-1809.

  197. Delmas P, et al. Effects of Raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. NEJM 1997;337:1641-1647.

  198. Meunier PJ, et al. Treatment of postmenopausal women with osteoporosis for low bone density with Raloxifene. Osteoporosis Int 1999;10:330-336.

  199. Ettinger B, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with Raloxifene. JAMA 1999;282:637-645.

  200. Siris ES. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study. J Bone Mine Res 2005;20(9):1514-1524.

  201. Cummings SR, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial: Multiple Outcomes of Raloxifene Evaluation. JAMA 1999;281:2189-2197.

  202. Vogel VG, et al. Effects of Tamoxifen vs Raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2727-2741.

  203. Meunier PJ, et al. The effect of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. New Engl J Med 2004;350:459-468.

  204. Regnister JY, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of peripheral osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005;90:2816-2822.

  205. Neer RM, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Eng J Med 2001;344:1434-1441.

  206. Shrader SP, et al. Parathyroid hormone (1-84) and treatment of osteoporosis. Ann Pharmacother 2005;39:1511-1516.

  207. Prince R, et al. Susteined nor vertebral fragility fracture risk reduction alter discontinuation of teriparatide treatment. J Bone Mine Res 2005;20:1507-1513.

  208. Chestnut CH, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonina in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000;109:267-276.

  209. Punn KK, Chan LWL. Analgesic effect of intranasal salmon calcitonin in the treatment of osteoporotic vertebral fractures. Clin Ther 1989;11:205-209.

  211. ÓRGANOS BLANCOS.

  213. Doherty JA, Cushing-Haugen KL, Saltzman SS, et al. Longterm use of postmenopausal estrogen and progestin hormone therapies and the risk of endometrial cancer. Am J Obstet Gynecol 2007;197(2):139.e1-7.

  214. The Writing Group for the PEPI trial. Effects of hormone replacement therapy on endometrial biopsy in postmenopausal women. JAMA 1996;275:370-375.

  215. Anderson GL, Judd HL, Kauniu AM, et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women’s Health Initiative Randomized Trial. JAMA 2003;290:1739-1748.

  216. Reid RL. Progestins in hormone replacement therapy: impact on endometrial and breast cancer. J SOGC 2000;22:677-681.

  217. Hill DA, Weiss NA, Beresford SA, et al. Continuous combined hormone replacement therapy and risk of endometrial cancer. Am J Obstet Gynecol 2000;183:1456-1461.

  218. Jirecek S, Lee A, Pavo I, et al. Raloxifene prevents the growth of uterine leiomyomas in premenopausal women. Fertil Steril 2004;81:132-136.

  219. Barakatt RR, Bundy BH, Spirtos NM, et al. Randomized doubleblind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol 2006;24:587-592.

  220. Committee on Gynecologic Practice. Hormone replacement therapy in women treated for endometrial cancer. ACOG Committee Opinion (No. 234). Int J Gynaecol Obstet 2001;73:283-284.

  221. Bertelli G, Vemurini M, Del Mastro L, et al. Tamoxifen and the endometrium: findings of pelvic examination and endometrial biopsy in asymptomatic breast cancer patients. Breas Cancer Res Treat 1998;47;41-46.

  222. Beral V, Bull D, Reeves G. Endometrial cancer and hormone replacement therapy in the Million Women Study. Lancet 2005;365:1543-1551.

  223. Archer DF, Hendrix S, Gallagher JC, et al. Endometrial effects of tibolone. J Clin Endocrinol Metabol 2007;92:911-918.

  224. Wright PK, May F, Darby S, Saif R, et al. Estrogen Regulates Vesicle Trafficking Gene Expression in EFF-3, EFM-19 and MCF- 7 Breast Cancer Cells. Int J Clin Exp Pathol 2009;2(5):463-475.

  225. Santen R, et al. Steroid enzymes and cancer. Ann NY Acad Sci 2009;55:132-140.

  226. Bulun SE, et al. Steroid enzymes and cancer. Ann NY Acad Sci 2009;55:121-131.

  227. Sepkovic DW, Bradlow HL. Steroid enzymes and cancer. Ann NY Acad Sci 2009;55:57-67.

  228. Vazquez-Memije ME, et al. Cellular and functional analysis of four mutations located in the mitochondrial ATPase6 gene. J Cell Biochem 2009;106(5):878-886.

  229. Giamas G, et al. CK1 modulates the transcriptional activity of ER via AIB1 in an estrogen-dependent manner and regulates ER –AIB1 interactions. Nucleic Acids Res 2009;37:3110-3123.

  230. Warren R. Hormones and mammographic breast density. Maturitas 2004;49:67-78.

  231. Writing Group for the Women’s Health Initiative investigators. Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women’s Health Initiative Randomized Controlled Trial. JAMA 2002;288:321-333.

  232. Pines A, Sturdee DW, Birkhäuser MH, et al. IMS update recommendations on postmenopausal hormone therapy. Climateric 2007;10(3):181-194.

  233. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. The Women’s Health Initiative Randomized Trial. JAMA 2003;289:3243-3253.

  234. Anderson GL, Chlebowski RT, Rossouw JE, et al. Prior hormone therapy and breast cancer risk in the Women’s Health Initiative randomized trial of estrogen plus progestin. Maturitas 2006;55:103-115.

  235. Scheele F, Burger CW, Kenemans P. Postmenopausal hormone replacement in the woman with a reproductive risk factor for breast cancer. Maturitas 1999;33:191-196.

  236. Collaborative group on hormonal factors in breast cancer. Breast cancer and hormone therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997:350:1047-1059.

  237. Beral V, Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362(9382):419-427.

  238. The Women’s Health Initiative Steering Comitte. Effects of Conjugated Equine Estrogen in Postmenopausal Women With Hysterectomy: The Women’s Health Initiative Randomized Controlled Trial. JAMA 2004;291:1701-1712.

  239. Graham JD, et al. DNA Replication Licensing and Progenitor Numbers Are Increased by Progesterone in Normal Human Breast. Endocrinology 2009;150:3318-3326.

  240. Singletary E. Rating the risk factors for breast cancer. Annals of Surgery 2003;237:474-482.

  241. Gareth ER, Howell A. Breast cancer risk assessement models. Breast Cancer Research 2007;9:213-220.

  242. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81:1879-1886.

  243. Spiegelman D, Colditz GA, Hunter D, et al. Validation of the Gail model for predicting individual breast cancer risk. J Natl Cancer Inst 1994;86:600-607.

  244. Costantino JP, Gail MH, Pee M, et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 1999;91:1541-1548.

  245. Rockhill B, Spiegelman D, Byrne C, et al. Validation of the Gail model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst 2001;93:358-366.

  246. Gail MH, Costantino JP. Validating and improving models for projecting the absolute risk of breast cancer. J Natl Cancer Inst 2001;93:334-335.

  247. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-1388.

  248. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005;97:1652-1662.

  249. Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomized chemoprevention trial. Lancet 1998;352:98-101.

  250. Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomized trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 1998;352:93-97.

  251. Veronesi U, Maisonneuve P, Rotmensz N, et al. Italian randomized trial among women with hysterectomy: tamoxifen and hormonedependent breast cancer in high-risk women. J Natl Cancer Inst 2003;95:160-165.

  252. Cuzick J, Forbes J, Edwards R, et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomized prevention trial. Lancet 2002;360:817-824.

  253. Vogel VG, Costantion JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2727-2741.

  254. Decensi A, Robertson C, Viale G. A randomized trial of low dose tamoxifen on breast cancer proliferation and circulating estrogenic biomarkers. J Natl Cancer Inst 2003;95:779-790.

  255. Bevers TB. Breast cancer chemoprevention: current clinical practice and future direction. Biomed Pharmacother 2001;55:559-564.

  257. METABOLISMO Y ENFERMEDAD CARDIOVASCULAR.

  259. Posadas RC, Yamamoto KL, Tapia CR. Epidemiología de las dislipidemias en México. En: Posadas RC. Dislipidemias y aterosclerosis. México:Interamericana, 1995;p:117.

  260. Morato HL, Lerman GI. Dislipidemias en el climaterio femenino y en ancianos. En: Posadas RC. Dislipidemias y aterosclerosis. México:Interamericana, 1995;p:159-170.

  261. Lobo RA. Effects of hormonal replacement on lipids and lipoproteins in postmenopausal women. J Clin Endoc Metab 1991;73:925-931.

  262. O’Brien T, Nguyen TT. Lipids and lipoproteins in women. Mayo Clin Proc 1997;72(3): 235-244.

  263. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen-progestin regimens on heart disease risk factors in postmenopausal women: the postmenopausal estrogen/progestin interventions (PEPI) Trial. JAMA 1995;273:199-204.

  264. Writing Group for the Women’s Health Initiative Investigators. Risks and Benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the WHI randomized controlled trial. JAMA 2002;288:321-333.

  265. Shilipak MG, Chaput LA, Vittinghoff E, et al. Lipids changes on hormone therapy and coronary heart disease events in HERS Study. Am Heart J 2003;146(5): 870-875.

  266. Gaspard UJ, Gottal JM, van den Breele FA. Postmenopausal changes of lipid and glucose metabolism; a review of their main aspects. Maturitas 1995;21:171-178.

  267. Crespo CJ, Smit E, Snelling A, Sempos CT, Andersen RE. Hormone Replacement Therapy and its Relationship to lipid and glucose metabolism in diabetic and non-diabetic Postmenopausal Women. Diabetes Care 2002;25(10).

  268. Howard N, Hodis MD, Wendy JM. Postmenopausal Hormone Therapy and Cardiovascular Disease in Perspective. Clinical Obstetrics and Gynecology 2008;51(3):564-580.

  269. Katherine MN, Buist DSN, Yu O, et al. Hormone Therapy initiation after the Womens’s Health Initiative. Menopause: The Journal of The North American Menopause Society 2008;15(3):487-493.

  270. Hsia J, Langer RD, Manson JE, et al. Conjugated equine estrogens and coronary heart disease: the Women’s Health Initiative. Arch Intern Med 2006;166:357-365.

  271. Prentice RL, Langer RD, Stefanick ML, et al. Combined analysis of Women’s Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease. Am J Epidemiol 2006;163:589-599.

  272. Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Women’s Health 2006;15:35-44.

  273. Bonita R. Epidemiology of stroke. Lencet 1992;339:342-344.

  274. Barrett-Connor E, Bush TL. Estrogen and coronary hearth disease in women. JAMA 1991;265:1861-1867.

  275. Wenger N, Speroff L, Packard B. Cardiovascular health and disease in women. N Engl J Med 1993;329:247-256.

  276. Bushnell CD, Hurn P, Colton C, et al. Advancing the study of stroke in women: summary and recommendations for future research from an NINDS-Sponsored Multidisciplinary Working Group. Stroke 2006;37:2387-2399.

  277. Estadísticas de mortalidad. .

  278. Birge S. Hormone therapy and stroke. Clin Obst Gynecol 2008;51:581-591.

  279. Bath PM, Gray LJ. Association between hormone replacement therapy and subsequent Stroke; a meta-analysis. BMJ 2005;330:342-345.

  280. Lobo RA. Menopause and stroke and the effects of hormonal therapy. Climateric 2007;10(Suppl. 2):27-31.

  281. Grodstein F, Manson EL, et al. Postmenopausal Hormone Therapy and Stroke: role of time since menopause and age at initiation of hormone therapy. Arch Intern Med 2008;168:861-866.

  282. Rossouw J, Prentice R, Manson J, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-77.

  283. Hendrix SL, Wassertheil-Smoller S, Johnson KC, et al. Effects of conjugated equine Estrogen on stroke in the Women’s Health Initiative. Circulation 2006;113:2425-2434.

  284. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women’s Health Initiative: a randomized trial. JAMA 2003;289:2673-2684.

  285. Lemaitre RN, Weiss NS, Smith NL, et al. Esteriefed estrogen and conjugated equine estrogen and the risk of incident myocardial infarction and stroke. Arch Intern Med 2006;166:389-399.

  286. Cummings SR, Ettinger B, Delmas PD, et al. For the LIFT Trial Investigators. The Effects of Tibolone in Older Postmenopausal Women. N Engl J Med 2008;359:697-708.

  287. Koh KK. Effects of estrogen on the vascular wall: vasomomotor function and inflammation. Cardiovasc Res 2002;55:714-726.

  288. Koh KK, Horne MKI, Canon RO III. Effects of hormone replacement therapy on coagulation, fibrinolysis, and thrombosis risk in posmenopausal women. Thromb Haemost 1999;82:626-633.

  289. Anderson FA Jr, Wheeler HB, Goldberg RJ, et al. A populationbased perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DT Study. Arch Intern Med 1991;151:933-938.

  290. Gerstman BB, Piper JM, Tomita DK, et al. Oral contraceptive estrogen dose and the risk of deep venous thoromboembolic disease. Am J Epidemiol 1991;133:32-37.

  291. Grodstein F, Stampfer M, Goldhaber S, et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996;348:983-987.

  292. Daly E, Vessey MP, Painter R, Manson I, et al. Case-control study of venous thromboembolism risk in users of hormone replacement therapy. Lancet 1996;348:1027.

  293. Jick H, Derby L, Myers M, Vasilaskis C. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996;348:981-983.

  294. Varas-Lorenzo C, García Rodríguez L, Cattaruzzi C, et al. Hormone replacement therapy and the risk of hospitalization for venous thrombolism: a population-based study in Southern Europe. Am J Epidemiol 1998;147:387-390.

  295. Douketis JD, Julian JA, Keaton C, et al. Does the type of hormone replacement therapy influence the risk of deep vein thrombosis? A prospective case-control study. J Thromb Haemostasis 2005;3:943-948.

  296. Cushman M, Kulleror LH, Prentice R, for the Women’s Health Initiative Investigators. Estrogen plus progestin and risk of venous thrombosis. J Am Med Assoc 2004;292:1573-1580.

  297. Smith NL, Heckbert SR, Lemaitre RN, et al. Esterifed estrogens and conjugated equine estrogens and the risk of venous thrombosis. J Am Med Assoc 2004;292:1581-1587.

  298. Scarabin P, Oger E, Plus-Bureau G, on behalf of the Estrogen and THromboEmbolism Risk (ESTHER) Study Group. Diferential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003;362:428-432.

  299. Grady D, Wenger NK, Herrington D, et al, for the Heart and Estrogen/progestin Replacement Study Research Group. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen-Progestin Replacement Study. Ann Intern Med 2000;132:689-696.

  300. Canonico M, Plu-Bureau G, Lowe G, Scarabin PS. Hormone replacement therapy and risk of venous troboembolism in posmenopausal women: systematic review and meta analysis. BMJ 2008;336:1227-1231. Originally published online 20 May 2008.

  301. The IDF Consensus Worldwide Definition of the Metabolic Syndrome, 2005. http://www.idf.org.

  302. Kannel WB, McGee DL. Diabetes and cardiovascular risk factor: the Framingham Heart Study. Circulation 1979;59:8.

  303. Lorenzo C, Williams K, González-Villalpando C, Haffner SM. The prevalence of the metabolic syndrome did not increase in mexico city between 1990-1992 and 1997-1999 despite more central obesity. Diabetes Care 2005;28:2480.

  304. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F; American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/ National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112(17):2735-52.

  305. González A, y col. Posición de Consenso. Recomendaciones para el diagnóstico, estratificación del riesgo cardiovascular, prevención y tratamiento del síndrome metabólico. Rev Mex Cardiol 2006;17(1).

  306. Shifren JL. Androgens, estrogens, and metabolic syndrome at midlife. Editorials. Menopause 2009;16(2):226-228.

  307. Salpeter SRJ, Walsh TM, Ormiston E, Greyber NS. Metaanalysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes, Obesity and Metabolism 2006;8:538-554.

  308. Janssen I, Powell LH, Crawford S, Lasley B, Sutton-Tyrrell K. Menopause and the metabolic syndrome: the Study of Women’s Health Across the Nation. Arch Intern Med 2008;168:1568- 1575.

  309. Lobo RA. Metabolic syndrome and the menopause. Maturitas 2008;60(1):10-8. Date of Electronic Publication: 2008 Apr 14.

  310. Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL. Increasing prevalence of overweight among US adults: The National Health and Nutrition Examination Surveys, 1960 to 1991. JAMA 1994;272:205-211.

  311. Kaaja RJ. The metabolic syndrome in postmenopausal women. Clinical implications. Menopause 2008;14(1): 21-25.

  312. Royer M. The US National Cholesterol Education Programme Adult. Treatment Panel III (NCEP ATP III): prevalence of the metabolic syndrome in postmenopausal Latin American women. Climateric 2007;10:164-170.

  313. Gambacciani M, et al. Body weight, body fat distribution, and hormonal replacement therapy in early postmenopausal women. J Clin Endocrinol Metab 1997;82(2):414.

  314. Burger HG, et al. The endocrinology of the menopausal transition: a cross-sectional study of a population-based simple. J Clin Endocrinol Metab 1995;80:3537.

  315. Haarbo J, et al. Postmenopause hormonal replaccement therapy prevent central distribution of body fat alter menopause. Metabolism 1991;40(12):1323.

  316. Gambacciani M, et al. Prospective evaluation of body weight and body fat distribution in early postmenopausal women with and without hormonal replaccement therapy. Maturitas 2001;39:125.

  318. TRATAMIENTO.

  320. North American Menopause Society. Estrogen and progestogen use in postmenopausal women: position statement of The North American Menopause Society. Menopause 2008;15:584-602.

  321. International Menopause Society. Recommendations on postmenopausal hormone therapy. 2007. www.imsociety.org. Consultado el 20 de marzo del 2009.

  322. Norma Oficial Mexicana NOM-035-SS2-2002. Prevención y control de enfermedades en la perimenopausia y postmenopausia de la mujer. Criterios para brindar atención médica.

  323. Basaria S, Dobs AS. Safety and adverse effects of androgens: how to counsel patients. Mayo Clin Proc 2004;79(4 Suppl.):S25-S32.

  324. Society of Obstetricians and Gynaecologists of Canada. Canadian Consensus Conference on Menopause, 2006 Update. JOGC 2006:28.

  325. National Institutes of Health. Clinical Guidelines on the Identification, Evaluation and Treatment of overweight and obesity in adults-the evidence report. National Institutes of Health. Obes Res 1999;6(Suppl. 2):51s.

  326. The American College of Obstetricians and Gynecologists. Clinical Updates in Women’s Health Care. Weight Control: Assesment and Management. The American College of Obstetricians and Gynecologists 2006;5(5).

  327. Institute for Clinical Systems Improvement (ICSI). Menopause and hormone therapy: collaborative decision-making and management. 2006. www.icsi.org. Accesado 20 mar 09.

  328. Grupo de trabajo de menopausia y postmenopausia. Guía de práctica clínica sobre la menopausia y postmenopausia. Barcelona: Sociedad Española de Ginecología y Obstetricia, Asociación Española para el Estudio de la Menopausia, Sociedad Española de Medicina de Familia y Comunitaria y Centro Cochrane Iberoamericano, 2004.

  329. Humphrey LL, Helfand M, Chan BK, et al. Breast cancer screening: a summary of the evidence for the US preventive Services Task Force. Ann Intern Med 2002;137:347-360.

  330. Norma Oficial Mexicana NOM-041-SSA2-2002 para la prevención, diagnóstico, tratamiento, control y vigilancia epidemiológica del cáncer de mama, 2003.

  331. Modificación a la Norma Oficial Mexicana NOM-014- SSA2-1994 para la prevención, detección, diagnóstico, tratamiento, control y vigilancia epidemiológica del cáncer cérvico uterino, 2007.

  332. National Heart, Lung and Blood Institute. Third report on the National Cholesterol Education Program expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adult treatment poanel III). Bethesda: NHLBI 2002 publication No 02-5215.

  333. Burger HG. Testosterone changes in women with age and menopause. Menopausal Medicine ASRM 2005;13:1-4.

  334. Rodríguez RS. Libro salud posmenopáusica. 1a ed. México, 2005;p:125-129.

  335. North American Menopause Society. Menopause Practice: a clinician Guide. 3th ed. EUA, 2007;p:59.

  336. Wierman ME, Basson R, Davis SR, et al. Clinical Practice Guideline. Androgen therapy in women: an Endocrine Society Clinical Practice guideline. J Clin Endocrinol & Metab 2006;91:3697-3710.

  337. North American Menopause Society. Position statement the role of testosterone therapy in postmenopausal women. Menopause 2005;12:497-511.

  338. Braunstein GD, Sundwall DA, Katz M, et al. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women. Arch Intern Med 2005;165:1582-1589.

  339. Shifren JL, Braunstein GD, Simon JA, et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. NEJM 2000;343:682-688.

  340. Buster JE, Kingsberg SA, Aguirre O, et al. Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. Obstet Gynecol. 2005;105:944-952.

  341. Shifren JL, Davis SR, Moreau M, et al. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 Study. Menopause. 2006;13:770-779.

  342. Davis SR, Van der Mooren MJ, Van Lunsen RH, et al. Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Menopause. 2006;13:387-396.

  343. Schover LR. Androgen therapy for loss of desire in women: is the benefit worth the breast cancer risk? Fertil Steril 2008;90:129-140.

  344. Davis SR, Monreau M, Kroll R, et al. For the APHRODITE Study Team. Testosterone for low libido in postmenopausal women not taking estrogen. NEJM 2008;359:2005-2007.

  345. Maia H Jr, Casoy J, Valente J. Testosterone replacement therapy in the climacteric: benefits beyond sexuality. Gynecol Endocrinol 2009;25:12-20.

  346. Ravnikar VA. Use of DHEA in menopause practice. Menopausal Medicine ASRM 2004;12:10-12.

  347. Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric 2005;8(Suppl. 1):3-63.

  348. Sittruk-Ware R. New hormonal therapies and regimens in the postmenopause: routes of Administration and timing of initiation. Climacteric 2007;10:358-370.

  349. Utian WH, Archer DF, Bachmann GA, et al. North American Menopause Society. Estrogen and progestogen use in postmenopausal women. July 2008 position statement of The North American Menopause Society. Menopause 2008;15:584-602.

  350. Hsia J, Langer RD, Manson JE, et al. Conjugated equine estrogens and coronary heart disease: the Women’s Health Initiative. Arch Inter Med 2006;13;166(3):357-365.

  351. Grodstein, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Women’s Health 2006;15:35-44.

  352. Pines A, Sturdee DW, Birkhäuser M. International Menopause Society. More data on hormone therapy and coronary heart disease: Comments on recent publications from the WHI and nurses’ health study. Climateric 2006;9:75-76.

  353. Herjan JT, CoelinghBennink. Are all estrogens the same? Maturitas 2008;61:(1-2)195-201.

  354. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1997;350:1047-59.

  355. Burger H. WHI risks: any relevance to menopause management? Maturitas 2007;57:6-10.

  356. Anderson GL, Limacher M, Assaf AR, et al. Women’s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712.

  357. Chen WY, Manson JE, Hankinson SE, et al. Unopposed estrogen therapy and the risk of invasive breast cancer. Arch Intern Med 2006;166:1027-1032.

  358. Lyytinen H, Ukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estrogen-only therapy. Obstet Gynecol 2006;108(6):1354-1360.

  359. Gompel A, Barlow D, Rozenberg S, et al. Breast cancer risk in postmenopausal women using estrogen-only therapy. Maturitas 2007;56:227-229.

  360. Farquhar C, Marjoribanks J, Lethaby A, et al. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2009 15;(2):CD004143.

  361. Birkhäuser MH, Panay N, Archer DF, et al. Updated practical recommendations for hormone replacement therapy in the peri- and postmenopause. Climacteric 2008;11:108-123.

  362. Menon DV, Vongpatanasin W. Effects of transdermal estrogen replacement therapy on cardiovascular risk factors. Treat Endocrinol 2006;5(1):37-51.

  363. Pines A, Sturdee DW, Birkhäuser MH, et al. IMS Updated Recommendations. Climacteric 2007;10(3):181-194.

  364. Beral V, Banks E, Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 2002;360:942-944.

  365. Haimov-Kochman R, Barak-Glantz E, Arbel R, et al. Gradual discontinuation of hormone therapy does not prevent the reappearance of climacteric symptoms: a randomized prospective study. Menopause 2006;13:370-376.

  366. Aslan E, Bagis T, Kilicdag EB, et al. How best is to discontinue postmenopausal hormone therapy: immediate or tapered? Maturitas 2007;56(1):78-83.

  367. Haimov-Kochman R, Barak-Glantz E, Ein-Mor E, et al. Duration not severity of the climacteric syndrome predicts resumption of hormone therapy after discontinuation: a prospective cohort study. Hum Reprod. 2006;21(9):2450-2454.

  368. Simon JA, Wehren LE, Ascott-Evans BH, et al. Skeletal consecuences of HT discontinuation. A systematic review. Obstet Gynecol Surv 2006;61(2):115-124.




2020     |     www.medigraphic.com